Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
38.35
-0.44 (-1.13%)
At close: Aug 28, 2025, 4:00 PM
38.35
0.00 (0.00%)
After-hours: Aug 28, 2025, 4:11 PM EDT
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 4 analysts that cover Collegium Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $44.25, which forecasts a 15.38% increase in the stock price over the next year. The lowest target is $37 and the highest is $50.
Price Target: $44.25 (+15.38%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $44 | Strong Buy | Initiates | $44 | +14.73% | Aug 11, 2025 |
| Piper Sandler | Piper Sandler | Hold Reiterates $36 → $37 | Hold | Reiterates | $36 → $37 | -3.52% | May 9, 2025 |
| Needham | Needham | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +19.95% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +30.38% | Mar 24, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $37 → $36 | Hold | Maintains | $37 → $36 | -6.13% | Feb 4, 2025 |
Financial Forecast
Revenue This Year
771.84M
from 631.45M
Increased by 22.23%
Revenue Next Year
793.33M
from 771.84M
Increased by 2.78%
EPS This Year
8.43
from 1.86
Increased by 353.79%
EPS Next Year
8.51
from 8.43
Increased by 0.96%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 812.0M | 829.2M | |||
| Avg | 771.8M | 793.3M | |||
| Low | 728.1M | 736.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.6% | 7.4% | |||
| Avg | 22.2% | 2.8% | |||
| Low | 15.3% | -4.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.99 | 11.30 | |||
| Avg | 8.43 | 8.51 | |||
| Low | 6.85 | 6.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 492.1% | 34.1% | |||
| Avg | 353.8% | 1.0% | |||
| Low | 269.0% | -22.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.